<DOC>
	<DOCNO>NCT01270789</DOCNO>
	<brief_summary>Type 2 diabetes mellitus ( T2DM ) chronic metabolic disorder characterize progressive deterioration function pancreatic beta-cells , cell produce secrete insulin ( hormone primarily responsible handle glucose body ) . We propose double-blind , randomize control study compare effect liraglutide ( novel anti-diabetic drug beta-cell protective potential ) versus placebo , preservation beta-cell function one year patient T2DM . This study may demonstrate important beta-cell protective capacity liraglutide .</brief_summary>
	<brief_title>LIraglutide Beta-cell RepAir ( LIBRA ) Study</brief_title>
	<detailed_description>In study , patient type 2 diabetes meet randomization criterion randomize either liraglutide placebo , serial assessment beta-cell function 48 week follow-up . The hypothesis study whether liraglutide preserve beta-cell function .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>men woman age 30 75 year inclusive physiciandiagnosed type 2 diabetes &lt; /= 7 year duration negative antiGAD antibody 02 oral antidiabetic medication A1c screen 5.5 % 9.0 % inclusive , oral antidiabetic medication , 6.0 % 10.0 % inclusive , oral antidiabetic medication use insulin , GLP1 agonist , dipeptidyl peptidase4 ( DPP4 ) inhibitor type 1 diabetes secondary form diabetes major illness life expectancy &lt; 5 year involvement another study require drug therapy hypersensitivity insulin , liraglutide , metformin renal dysfunction hepatic dysfunction history pancreatitis family personal history Multiple Endocrine Neoplasia type 2 ( MEN2 ) familial medullary thyroid carcinoma personal history nonfamilial medullary thyroid carcinoma malignant neoplasm require chemotherapy , surgery , radiation palliative therapy within previous 5 year ( exception basal cell skin cancer ) excessive alcohol consumption unwillingness undergo multiple daily insulin injection therapy unwillingness perform capillary blood glucose monitoring least 4 time per day intensive insulin therapy congestive heart failure pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>beta-cell function</keyword>
	<keyword>GLP-1 analogue</keyword>
	<keyword>diabetes</keyword>
</DOC>